CL

Business profile & competitive position

Colgate-Palmolive Company is a Consumer Defensive name in the Household & Personal Products industry. Its operating model is built around two segments: Oral, Personal and Home Care, which covers toothpaste, toothbrushes, soaps, deodorants, skin health products, cleaners and fabric conditioners; and Hill’s Pet Nutrition, which sells specialty dog and cat foods. The company sells into more than 200 countries and territories through retailers, wholesalers, eCommerce platforms, veterinarians and certain direct-to-consumer channels.

In 2025, Oral Care alone accounted for 44% of worldwide net sales, Pet Nutrition contributed 23%, Personal Care 17% and Home Care 16%. That revenue mix points to a concentrated reliance on oral-care brands, but with meaningful diversification into pet nutrition and personal-care categories. The company’s net margin of 9.7% signals a reasonably profitable, high-volume consumer staples operation, while the reported ROE of 631.1% is extraordinarily high. Such a figure generally reflects significant leverage or a very small equity base rather than pure operating returns, so it should be read as a capital-structure signal—likely shaped by buybacks, dividends and accumulated retained-earnings dynamics—rather than proof of a widening competitive moat on its own. What the margin and global scale do suggest is a business with pricing power in everyday categories and repeat-purchase demand.

Financial posture

As of the snapshot date, Colgate-Palmolive carried a market capitalization of $72.1 billion and traded at a P/E of 35.4. That is a premium multiple by consumer-staples standards, implying the market is assigning significant value to earnings stability and brand durability rather than to dramatic growth. The 9.7% net margin supports the idea of a cash-generative business, though a P/E above 35 means the stock is priced for consistent execution.

The beta of 0.33 is notably low, confirming the defensive characteristics typical of the Household & Personal Products classification. A beta that low suggests the stock has historically moved less than one-third as much as the broad market during risk-on or risk-off periods. The 631.1% ROE, again, is less about operational intensity and more about how efficiently equity capital has been deployed or returned to shareholders. No specific debt figure is provided in the current data, so any leverage interpretation should be treated as hypothetical until confirmed by the balance sheet.

Strategic priorities & outlook

According to the company’s most recent SEC 10-K filing, Colgate-Palmolive’s overarching priorities center on driving organic sales growth and delivering consistent, compounded earnings-per-share growth. Operational execution is framed around achieving efficiency gains while growing free cash flow and using the balance sheet efficiently. The company also emphasizes leveraging its global brand reach, science-based innovation, an agile supply chain and best-in-class omni-channel demand generation.

Beyond products and distribution, the 10-K highlights capability building in data, analytics and artificial intelligence, alongside efforts to evolve a high-impact, inclusive culture. Operationally, Walmart and its affiliates represented approximately 11% of 2025 net sales, with no other customer exceeding 10%, which creates a notable, if not extreme, customer-concentration dynamic. The company employed roughly 33,600 people across more than 100 countries as of December 31, 2025, with over 84% located outside the United States. That geographic footprint reinforces both the global diversification story and the importance of foreign-exchange, cross-border sourcing and international labor dynamics.

Macro & geopolitical exposure

Because Colgate-Palmolive sits in Household & Personal Products, its macro exposures are those typical of global consumer staples: input-cost inflation for commodities such as resins, surfactants, pulp-based packaging and agricultural-derived ingredients; currency translation, given that the vast majority of its workforce is outside the U.S.; and trade-policy changes including tariffs or cross-border logistics rules. Regulatory exposure also matters: personal-care and oral-care products face standards from agencies like the FDA as well as evolving rules on product safety, labeling, environmental packaging and ingredient transparency.

Demand itself tends to be non-discretionary—people continue brushing teeth, washing clothes and feeding pets through economic cycles—but volume can still be pressured by private-label competition, consumer trade-down and retailer consolidation. The 11% sales exposure to Walmart adds a layer of concentration risk common in U.S. staples. Supply-chain agility is therefore a recurring strategic theme, consistent with the 10-K’s emphasis on an agile supply chain and data-driven operations.

Recent developments

Recent headlines have framed Colgate-Palmolive largely as a quality defensive holding. On August 14, 2026, 247wallst.com included the company among “5 Dividend Kings to Buy and Hold Forever in August.” On August 12, 2026, zacks.com published multiple articles mentioning CL: “BJ or CL: Which Is the Better Value Stock Right Now?,” “4 Consumer Staples Stocks to Watch Amid Ongoing Industry Pressures,” and “Here's Why Colgate-Palmolive (CL) is a Strong Momentum Stock.” These titles reflect the broader market debate—whether CL’s premium valuation still looks attractive relative to peers, and whether staples as a group can hold momentum amid persistent margin and demand pressures.

Earnings behavior & post-earnings drift

Colgate-Palmolive’s earnings track record has been remarkably consistent. Over the last eight reported quarters, it beat consensus in all eight, for a 100% beat rate, with an average earnings surprise of 3.3%. The average five-day post-earnings move across those quarters has been +2.32%, classified as an upward drift.

The most recent quarters illustrate an interesting micro-pattern. For the July 31, 2026 report, CL posted actual EPS of $0.99 against an estimate of $0.947, a 4.5% beat, yet the stock fell 1.56% the next day before recovering to a 2.16% gain over the following five sessions. The May 1, 2026 quarter showed a 2.9% beat ($0.97 vs. $0.943) but a next-day drop of 2.17% and only a 0.33% five-day drift. By contrast, the January 30, 2026 report delivered a 4.2% beat ($0.95 vs. $0.912) and a strongly positive reaction: +1.77% the next day and +4.56% over five days. The October 31, 2025 report produced a 2.4% beat ($0.91 vs. $0.889) followed by a 2.69% next-day decline and a 2.22% five-day recovery.

This sequence suggests that beating the official consensus is not always enough to produce an immediate rally—the market's real expectation may already be tilted higher than the published estimate. Even so, the five-day drift has generally absorbed those next-day pullbacks and moved higher. CL is next scheduled to report on October 30, 2026, before the market opens, with a current consensus EPS estimate of $0.92. As a contextual snapshot, the stock was at $90.11 with an RSI of 42.9 and a 50-day EMA of $91.41, sitting slightly below that short-term average.

For a deeper dive, consider reviewing the full institutional verdict and consensus breakdown rather than relying on this single snapshot. This analysis is for informational purposes only and does not constitute investment advice.